Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma

被引：7
|
作者：
Rodgers, Thomas D. [1 ]
Baran, Andrea [1 ]
Reagan, Patrick M. [1 ]
Casulo, Carla [1 ]
Zent, Clive [1 ]
Evans, Andrew [2 ]
Burack, Richard [2 ]
Williams, AnnaLynn M. [1 ]
Friedberg, Jonathan W. [1 ]
Barr, Paul M. [1 ]
机构：
[1] Univ Rochester, Wilmot Canc Inst, Rochester, NY 14627 USA
[2] Univ Rochester, Dept Pathol, Rochester, NY 14627 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 188卷 / 04期
关键词：
NON-HODGKIN-LYMPHOMA; SINGLE-AGENT LENALIDOMIDE; RITUXIMAB;
D O I：
10.1111/bjh.16302
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E33 / +
页数：4
相关论文
共 50 条
  • [1] Efficacy and safety of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
    Habermann, T.
    Lossos, I.
    Justice, G.
    Tuscano, J.
    Cole, C.
    Vose, J.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Wiernik, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 150 - 150
  • [2] The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma
    Wei, Xiaolei
    Guo, Xutao
    Wei, Qi
    Xiong, Dan
    Zhang, Peng
    Zhang, Zewen
    Wei, Yongqiang
    Feng, Ru
    BLOOD, 2023, 142
  • [3] The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma
    Wei, Xiaolei
    Guo, Xutao
    Wei, Qi
    Xiong, Dan
    Zhang, Peng
    Zhang, Zewen
    Wei, Yongqiang
    Feng, Ru
    BLOOD, 2024, 144 : 1740 - 1740
  • [4] The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
    Palmieri, R.
    Esposito, F.
    Meconi, F.
    Rapisarda, V. M.
    Anemona, L.
    Paterno, G.
    Vaccarini, S.
    Nasso, D.
    Pupo, L.
    Cantonetti, M.
    CASE REPORTS IN HEMATOLOGY, 2019, 2019
  • [5] DIFFUSE LARGE B-CELL LYMPHOMA RESPONDS TO TAFASITAMAB PLUS LENALIDOMIDE
    不详
    CANCER DISCOVERY, 2020, 10 (08) : 1091 - 1091
  • [6] Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma
    Tanimoto, Tetsuya
    Oshima, Kumi
    Tsuda, Kenji
    Mori, Jinichi
    Shimmura, Hiroaki
    LANCET ONCOLOGY, 2017, 18 (10): : E557 - E557
  • [7] Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma
    Bobillo, Sabela
    Wilson, Matthew R.
    Cwynarski, Kate
    CURRENT OPINION IN ONCOLOGY, 2023, 35 (05) : 382 - 388
  • [8] Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
    Stokes, Matthew E.
    Wenzl, Kerstin
    Huang, C. Chris
    Estevez, Maria Ortiz
    Maurer, Matthew J.
    Stong, Nicholas
    Hagner, Patrick
    Nakayama, Yumi
    Hsu, Chih-Chao
    Danziger, Samuel A.
    Towfic, Fadi
    King, Rebecca L.
    Parker, Joel S.
    Link, Brian K.
    Slager, Susan L.
    Sarangi, Vivekananda
    Asmann, Yan
    Novak, Joseph P.
    Sudhindra, Akshay
    Ansell, Stephen M.
    Habermann, Thomas M.
    Nowakowski, Grzegorz S.
    Cerhan, James R.
    Novak, Anne J.
    Gandhi, Anita K.
    BLOOD, 2022, 140 : 3548 - 3550
  • [9] Enrollment of high-risk patients with diffuse large B-cell lymphoma in clinical trials.
    Loh, Kah Poh
    Baran, Andrea
    Hu, John
    Casulo, Carla
    Barr, Paul M.
    Friedberg, Jonathan W.
    Reagan, Patrick Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study
    Gonzalez-Barca, Eva
    Duell, Johannes
    Cavallo, Federica
    Sancho, Juan-Manuel
    Nagy, Zsolt
    Abrisqueta, Pau
    Panizo, Carlos
    Augustin, Marinela
    Weirather, Johannes
    Ambarkhane, Sumeet
    Maddocks, Kami J.
    Kalakonda, Nagesh
    Salles, Gilles
    BLOOD, 2020, 136
12345